Adverse Reactions to Tremelimumab, Durvalumab in Liver Cancer
In recent years, the advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape of hepatocellular carcinoma (HCC), a primary ...
In recent years, the advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape of hepatocellular carcinoma (HCC), a primary ...
In a groundbreaking study published in BMC Cancer, researchers have made strides in understanding and predicting liver injury induced by ...
A groundbreaking multinational study has shed new light on immune-mediated adverse events (irAEs) associated with the combination therapy of atezolizumab ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine